Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSRF 786C-ADC
- Development stage
- Preclinical
- Lead developer
- Tasrif Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TSRF 786C-ADC is an antibody-drug conjugate (ADC) currently in the discovery phase, developed by Tasrif Pharmaceutical for the treatment of cancer. It is designed to target the Poliovirus receptor (PVR), also known as CD155, a cell surface glycoprotein that is frequently overexpressed in various solid tumors and plays a significant role in tumor cell adhesion, migration, and immune evasion via its interaction with checkpoint receptors like TIGIT. The ADC consists of the TSRF 786C antibody conjugated to a cytotoxic payload. Upon binding to PVR on the surface of malignant cells, the conjugate is internalized, leading to the intracellular release of the payload and subsequent cell death. This targeted approach is intended to enhance therapeutic efficacy while reducing off-target systemic toxicity.
- Other names
- TSRF 786C antibody-drug conjugateTSRF786C antibody-drug conjugateTSRF-786C antibody-drug conjugate
02
Targets
PVR
Beyond the preview
Go deeper on TSRF 786C-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSRF 786C-ADC.